These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30526159)

  • 21. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
    Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
    J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monkey Models and HIV Vaccine Research.
    Chen Z
    Adv Exp Med Biol; 2018; 1075():97-124. PubMed ID: 30030791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current views on the potential for development of a HIV vaccine.
    Cohen KW; Frahm N
    Expert Opin Biol Ther; 2017 Mar; 17(3):295-303. PubMed ID: 28095712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV vaccine development: Lessons from the past, informing the future.
    Bradac J; Dieffenbach CW
    IDrugs; 2009 Jul; 12(7):435-9. PubMed ID: 19579164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects.
    Kaur A; Vaccari M
    Viruses; 2024 Feb; 16(3):. PubMed ID: 38543734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Encouraging vaccine results from primate models of HIV type 1 infection.
    Schultz A
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S261-3. PubMed ID: 9814953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.
    Dimitrov D; Kublin JG; Ramsey S; Corey L
    EBioMedicine; 2015 Dec; 2(12):2062-9. PubMed ID: 26844286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic and prophylactic DNA vaccines for HIV-1.
    Ramirez LA; Arango T; Boyer J
    Expert Opin Biol Ther; 2013 Apr; 13(4):563-73. PubMed ID: 23477730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
    O'Connell RJ; Kim JH; Excler JL
    Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-human primates in HIV research: Achievements, limits and alternatives.
    Garcia-Tellez T; Huot N; Ploquin MJ; Rascle P; Jacquelin B; Müller-Trutwin M
    Infect Genet Evol; 2016 Dec; 46():324-332. PubMed ID: 27469027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. (How) Can NHP MODELS ACCELERATE Vaccine Development?
    Schultz A
    IAVI Rep; 2015; 19(3):15-6. PubMed ID: 26647468
    [No Abstract]   [Full Text] [Related]  

  • 33. Worldwide survey of AIDS vaccine challenge studies in nonhuman primates: vaccines associated with active and passive immune protection from live virus challenge.
    Warren JT; Dolatshahi M
    J Med Primatol; 1992; 21(2-3):139-86. PubMed ID: 1433265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
    Sekaly RP
    J Exp Med; 2008 Jan; 205(1):7-12. PubMed ID: 18195078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress toward an HIV vaccine.
    Letvin NL
    Annu Rev Med; 2005; 56():213-23. PubMed ID: 15660510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonhuman primate models for evaluation of SARS-CoV-2 vaccines.
    Neil JA; Griffith M; Godfrey DI; Purcell DFJ; Deliyannis G; Jackson D; Rockman S; Subbarao K; Nolan T
    Expert Rev Vaccines; 2022 Aug; 21(8):1055-1070. PubMed ID: 35652289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.
    Bett AJ; Dubey SA; Mehrotra DV; Guan L; Long R; Anderson K; Collins K; Gaunt C; Fernandez R; Cole S; Meschino S; Tang A; Sun X; Gurunathan S; Tartaglia J; Robertson MN; Shiver JW; Casimiro DR
    Vaccine; 2010 Nov; 28(50):7881-9. PubMed ID: 20937317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surrogates of protection in repeated low-dose challenge experiments.
    Long DM; Hudgens MG; Wu CD
    Stat Med; 2015 May; 34(10):1747-60. PubMed ID: 25628249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. "In vitro systems to characterize the immune response to HIV-1 and HIV-1 vaccine candidates", NIAID Workshop Report, Bethesda, August 4, 2010.
    Malaspina A; Rinaldo CR; Sekaly RP; Flores J; D'Souza PM
    Vaccine; 2011 Jun; 29(29-30):4647-53. PubMed ID: 21571022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on mucosal HIV vaccine vectors.
    Duerr A
    Curr Opin HIV AIDS; 2010 Sep; 5(5):397-403. PubMed ID: 20978380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.